Anti-VEGF antibodies (intravitreal) prior authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 132.1 alerts
Get alerted when Policy 132.1 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and renewal requirements for intravitreal anti-VEGF antibody agents for retinal diseases for AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy
Covered when the following sequence of criteria is met as applicable to the requested agent:
If required prior failures/contraindications are not documented, deny
Coverage limited to preferred formulary biosimilar agent(s) where applicable and available
Renewal Therapy
Renewal covered when the following are met:
If a positive response is not documented, deny renewal
Coverage of intravitreal anti-VEGF therapy is subject to formulary preference: when a biosimilar or preferred formulary agent is applicable and available, coverage will be limited to that agent. The policy explicitly states there are no evidence‑based criteria to select among anti‑VEGF drugs and that real‑world choice is driven primarily by medication cost and insurance approval; therefore, prior authorization decisions will reflect formulary preference and biosimilar availability where indicated. (Approval lengths and quantity limits apply as described elsewhere in the policy.)
Requests will be denied if required documentation or eligibility elements are missing. Specifically, the request must document the member is ≥18 years, that the injection is requested by a retinal specialist (vitreoretinal surgeon or vitreoretinal specialist), and that the medical record supports a retinal diagnosis for which anti‑VEGF therapy is indicated. For agent‑specific approvals, documentation must also show the required prior treatment failures or contraindications (e.g., prior failure/contraindication to bevacizumab for ranibizumab; to bevacizumab and ranibizumab for aflibercept; and to bevacizumab, ranibizumab, and aflibercept for aflibercept HD or faricimab). If these elements are not provided, the request does not meet criteria and will be denied or forwarded to physician review per policy.
Coding and Included Agents
| Bevacizumab | Agent included in criteria |
| Ranibizumab | Lucentis, Byooviz, Cimerli — agent included in criteria |
| Aflibercept | Eylea, Yesafili, Opuviz, Ahzantive — agent included in criteria |
| Aflibercept (Eylea HD) | Agent included in criteria |
| Faricimab | Vabysmo — agent included in criteria |
Provider Actions, Documentation & Step Therapy
Prior authorization required; approval up to 12 months
Prior authorization is required for intravitreal anti‑VEGF therapy; coverage is limited to preferred formulary biosimilar agent(s) where applicable and available. When criteria are met, approvals are issued for up to 12 months.
Step/failure hierarchy required for agent selection
Approval of a requested agent requires documentation of prior treatment failure or a contraindication to earlier, preferred agents in a stepwise hierarchy: bevacizumab first, then ranibizumab, then aflibercept, then aflibercept HD or faricimab as applicable to the requested agent.
- Ranibizumab: documentation of prior failure or contraindication to bevacizumab is required.
- Aflibercept: documentation of prior failure or contraindication to bevacizumab and ranibizumab is required.
- Aflibercept HD or Faricimab: documentation of prior failure or contraindication to bevacizumab, ranibizumab, and aflibercept is required.
Required documentation to support request
Submit documentation that supports age, diagnosis, provider specialty, prior treatments, and for renewals, response to treatment. Documentation must show the member is ≥18, that a retinal diagnosis indicates anti‑VEGF therapy, that the administering provider is a retinal specialist, and any required prior treatment failures or contraindications.
- Patient age (≥18 years).
- Retinal diagnosis for which anti‑VEGF therapy is indicated.
- Administering provider specialty (vitreoretinal surgeon or vitreoretinal specialist).
- Documentation of prior treatment failure or contraindication to required prior agents as applicable.
- For renewals: chart documentation of a positive clinical response.
Administering provider must be a retinal specialist
Requests for intravitreal injection must be submitted by a retinal specialist (vitreoretinal surgeon or vitreoretinal specialist); requests by non‑retinal specialists will be denied.
Minimum age ≥18 years (under 18 forwarded to MD)
Members must be at least 18 years old for initial eligibility; requests for members under 18 are forwarded to a medical director for review or do not meet criteria.
Diagnosis must support indication; otherwise deny
If submitted documentation does not support a retinal diagnosis for which anti‑VEGF therapy is indicated, the request will be denied.
Denied if prior‑failure/contraindication documentation missing
If documentation does not show the required prior treatment failure(s) or contraindication(s) to the specified prior agents for the requested drug, the request will be denied.
- Lack of documented failure or contraindication to bevacizumab will result in denial for ranibizumab requests.
- Lack of documented failure or contraindication to bevacizumab and ranibizumab will result in denial for aflibercept requests.
- Lack of documented failure or contraindication to bevacizumab, ranibizumab, and aflibercept will result in denial for aflibercept HD or faricimab requests.
Renewal requires documented positive clinical response
For renewal requests, the chart must document a positive clinical response to the requested treatment; absence of such documentation will result in denial.
- Renewal requires that the member met initial criteria and that a positive clinical response is documented.
- If positive response is not documented, the renewal is denied.
Background
Vascular endothelial growth factor (VEGF) inhibitors are administered intravitreally to reduce macular edema and improve vision by decreasing vascular permeability. Multiple anti‑VEGF agents are used clinically — including bevacizumab, ranibizumab, aflibercept, faricimab, and ranibizumab‑nuna — and have been shown in observational studies and randomized trials to be effective and generally well tolerated for retinal diseases. The policy notes ranibizumab is the only agent FDA‑approved for myopic choroidal neovascularization, while other agents may be used off‑label; overall coverage decisions are influenced by formulary preference, biosimilar availability, and insurance approval.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.